Gabelli Equity Trust: Rights Offering Analysis

Jun. 22, 2021 2:06 PM ETGabelli Equity Trust (GAB)67 Comments


  • GAB is in the middle of a 10-for-1 transferable rights offering.
  • The offering is likely to be dilutive due to the substantial discount that the new shares are offered at.
  • What should investors, who held through the ex-rights date and now own GAB rights, do?
  • Looking for a helping hand in the market? Members of CEF/ETF Income Laboratory get exclusive ideas and guidance to navigate any climate. Learn More »
Yahoo Finance All Markets Summit
Cindy Ord/Getty Images Entertainment

Author's note: This analysis was part of our CEF Weekly Roundup release to Income Lab members on June 8, 2021, and data are from that date unless otherwise stated. Please check latest data before investing.

This article analyzes The Gabelli Equity Trust's (NYSE:GAB) rights offering. From the press release:

Gabelli Equity Trust Announces Rights Offering for Shares of Common Stock Record Date and Summary of Terms

May 19, 2021 07:45 PM Eastern Daylight Time

The Board of Directors of The Gabelli Equity Trust Inc. (NYSE:GAB) (the “Fund”) has approved a transferable rights offering which would allow the Fund’s record date common shareholders to acquire additional shares of common stock (the “Offering”).

  • Each shareholder will receive one transferable right (the “Right”) for each share of common stock held on the record date (June 2, 2021).
  • Ten Rights plus $5.50 (the “Subscription Price”) will be required to purchase one additional share of common stock (the “Primary Subscription”). The purchase price will be payable in cash.
  • Record date shareholders who fully exercise their Primary Subscription Rights will be eligible for an over-subscription privilege entitling these shareholders to subscribe, subject to certain limitations and a pro-rata allotment, for any additional shares of common stock not purchased pursuant to the Primary Subscription. Rights acquired in the secondary market may not participate in the over-subscription privilege.
  • The Rights are expected to trade “when issued” on the New York Stock Exchange beginning on May 28, 2021, and the Fund’s shares of common stock are expected to trade “Ex-Rights” on the New York Stock Exchange beginning on June 1, 2021. The Rights are expected to begin trading for normal settlement on the New York Stock Exchange (NYSE:GAB RT) on or about June 7, 2021.
  • The Offering expires at 5:00 PM Eastern Time on July 14, 2021, unless extended.

When premiums are running high, it is actually a logical thing for managers to conduct a rights offering in order to monetize that premium and generate accretion for shareholders - although as we've seen time and time again, the short-term effects on the share price are usually detrimental. This is why we recommend selling CEFs that conduct rights offerings and then buy back shares later: one benefits both from the temporary price declines as well as the long-term performance boost that comes from accretion!

Ex-rights day drop relatively muted

In the case of GAB, the ex-rights date drop was relatively minor (19 cents, or -2.5% on June 1, 2021) compared to other funds.


Data by YCharts

This could be because of two reasons. Firstly, the fund wasn't trading at an egregious premium heading to the ex-rights date (it closed at a +10% premium the day before). Secondly, this is a transferable 10-for-1 offering meaning that each right is worth significantly less compared to a typical 3-for-1 offering.

Possible arbitrage opportunity available

The subscription price is fixed at $5.50, and at today's closing share price of $7.26 each right should be worth 17.5 cents. Meanwhile, the rights (GAB RT) closed at 9.45 cents, so we have another case of where rights are worth less than their intrinsic value.


This suggests an arbitrage opportunity where one could buy 10 rights for $0.945 and $5.50 (total $6.445) to subscribe for one new share of GAB which is worth $7.26, some +12.6% higher, on the open market. This is ostensibly a nice deal; however, the risk is that the price of GAB declines from now until the expiry date of July 14, 2021. So it might be worth waiting until the final one or two weeks to see if the arbitrage opportunity is still in play.

It should also be noted that the offering is likely to be dilutive given the fact that the fund's NAV currently stands at $6.92. However, since it is a 10-for-1 offering, the impact on NAV dilution is likely to be minor, around -1.9% at current NAV.

Update: What should GAB investors do?

GAB closed on June 21, 2021 with a price of $6.68, while the rights closed at 11.1 cents, which is actually right about what their intrinsic value should: 11.8 cents. The reason that the intrinsic value of the rights has fallen since our initial analysis is because GAB sold off sharply over the last couple of days.

Data by YCharts

This was partly due to the market sell-off but also partially due to the declining premium of the fund. While one cannot predict the former, the latter has been a typical behavior that we have observed for funds during their rights offerings periods (which is why we recommend our members to sell a fund when one is announced).

A corollary to this is that the arbitrage opportunity that we identified above is now significantly diminished.

What should GAB investors who own rights do now? The simple answer is that they should either subscribe for discounted GAB shares with the rights that they own, or else sell the rights on the open market. Since the rights are trading at around their intrinsic value, both options are about equivalent economically. Remember that either way, one should act before July 14, 2021 which is the expiry date of the offer (and brokers may have their own, earlier, internal deadlines). Letting the rights expire worthless would be the least ideal outcome.

For more information about the merits of GAB as a standalone investment, see Nick Ackerman's article here: GAB: High Yielding Equity Fund. (Disclosure: Nick is a member of the CEF/ETF Income Laboratory team and he had a neutral rating on the stock in his April 2021 review).

Profitable CEF and ETF income and arbitrage ideas At the CEF/ETF Income Laboratory, we manage closed-end fund (CEF) and exchange-traded fund (ETF) portfolios targeting safe and reliable ~8% yields to make income investing easy for you. Check out what our members have to say about our service.

To see all that our exclusive membership has to offer, sign up for a free trial by clicking on the button below!

This article was written by

Stanford Chemist profile picture
CEF/ETF income and arbitrage strategies, 8%+ portfolio yields

CEF/ETF Income Laboratory is a premium newsletter on Seeking Alpha that is focused on researching profitable income and arbitrage ideas with closed-end funds (CEFs) and exchange-traded funds (ETFs). We manage model safe and reliable 8%-yielding fund portfolios that have beaten the market in order to make income investing easy for you. Check us out to see why one subscriber calls us a "one-stop shop for CEF research.”

Click here to learn more about how we can help your income investing!

The CEF/ETF Income Laboratory is a top-ranked newsletter service that boasts a community of over 1000 serious income investors dedicated to sharing the best CEF and ETF ideas and strategies.

Our team includes:

1) Stanford Chemist: I am a scientific researcher by training who has taken up a passionate interest in investing. I provide fresh, agenda-free insight and analysis that you won't find on Wall Street! My ultimate goal is to provide analysis, research and evidence-based ways of generating profitable investing outcomes with CEFs and ETFs. My guiding philosophy is to help teach members not "what to think", but "how to think".

2) Nick Ackerman: Nick is a former Financial Advisor and has previously qualified for holding Series 7 and Series 66 licenses. These licenses also specifically qualified him for the role of Registered Investment Adviser (RIA), i.e., he was registered as a fiduciary and could manage assets for a fee and give advice. Since then he has continued with his passion for investing through writing for Seeking Alpha, providing his knowledge, opinions, and insights of the investing world. His specific focus is on closed-end funds as an attractive way to achieve income as well as general financial planning strategies towards achieving one’s long term financial goals.

3) Juan de la Hoz: Juan has previously worked as a fixed income trader, financial analyst, operations analyst, and economics professor in Canada and Colombia. He has hands-on experience analyzing, trading, and negotiating fixed-income securities, including bonds, money markets, and interbank trade financing, across markets and currencies. He is the "ETF Expert" of the CEF/ETF Income Laboratory, and enjoys researching strategies for income investors to increase their returns while lowering risk.

4) Dividend Seeker: Dividend Seeker began investing, as well as his career in Financial Services, in 2008, at the height of the market crash. This experience gave him a lot of perspective in a short period of time, and has helped shape his investment strategy today. He follows the markets passionately, investing mostly in sector ETFs, fixed-income CEFs, gold, and municipal bonds. He has worked in the Insurance industry in Funds Management, helping to direct conservative investments for claims reserves. After a few years, he moved in to the Banking industry, where he worked as a junior equity and currency analyst. Most recently, he took on an Audit role, supervising BSA/AML Compliance teams for one of the largest banks in the world. He has both a Bachelors and MBA in Finance. He is the "Macro Expert" of the CEF/ETF Income Laboratory.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (67)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.